An interventional study of Optimal medical therapy (OMT) and Catheter-based angiography in Renovascular Hypertension, Renovascular Hypertension With Renal Failure and Heart Failure, sponsored by University of Aarhus. Recruiting at 3 sites in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by University of Aarhus · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Heart Failure by University of Aarhus — 4 open to participants now, 4 under way, none of them phase 3. Heart Failure · University of Aarhus.
Among the 29 studies in Heart Failure by University of Aarhus, this one is the 6th largest by planned enrollment of the 22 interventional ones that give a count, is the only one that started in 2023, is one of 10 with no phase, and was the 26th registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →4 of the 29 studies in Heart Failure by University of Aarhus are open now, in 2 countries. Recruiting first, the newest first:
University of Aarhus · Sites in Denmark
Ages 18+
University of Aarhus · Sites in Denmark
Ages 18+
University of Aarhus · Sites in Denmark, Norway
Ages 18+
By country, each count listing its studies:
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is close to the median of 76 across 4,053 interventional studies indexed under Heart Failure.
Median enrollment 23 across the 22 interventional studies, 74 across the 7 observational. Of the 17 that completed or were terminated, 1 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Aarhus is the lead sponsor of 1,303 studies on the registry; 190 are open to participants now.
1 of the studies in Heart Failure by University of Aarhus that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05834803University of AarhusEffects of Percutaneous Transluminal Renal Angioplasty of Atherosclerotic Renal Artery Stenosis in High-Risk Patients. | 2027-06-01 |
Add it to your calendar (.ics) → With an account.
Among the 29 studies in Heart Failure by University of Aarhus, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to investigate whether percutaneous transluminal renal angioplasty (PTRA) with stent placement of atherosclerotic renal artery stenosis is beneficial in high-risk patients selected according to the criteria used in the DAN-PTRAI study. The main questions the trial aims to answer are whether renal artery stenting in addition to optimal medical therapy, compared with a sham procedure and optimal medical therapy, has beneficial effects on:
Even with optimal medical care, patients with renovascular disease have a very high risk of cardiovascular events and an expected poor outcome. One treatment option of atherosclerotic renal artery stenosis is percutaneous transluminal renal angioplasty with stent placement. Renal artery stenting is, however, still a subject of debate as randomized trials have failed to show a benefit of this compared with optimal medical treatment alone. Following the results of the large CORAL trial in 2014, we established the national prospective DAN-PTRAI study using strict and well-defined criteria to select patients for renal artery stenting. In this study, we observed a reduction in blood pressure, an improved kidney function, and a decrease in new hospital admissions due to heart failure after renal artery stenting.
The DAN-PTRAII study is a nationwide randomized, sham-controlled clinical trial in patients with severe renovascular disease due to atherosclerotic renal artery stenosis. Only patients who fulfill the inclusion criteria on optimal medical treatment can enter the study and only the operator and the interventional team will know whether the patients receive renal artery stenting or sham treatment. Participants will be followed closely for 6 months after the treatment to evaluate the effects of renal artery stenting compared with a sham procedure, both in addition to optimal medical therapy, on blood pressure, kidney function, and hospitalizations for heart failure.
The criteria were revised on the registry on Nov 4, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
In addition, at least one of the following high-risk clinical syndromes:
All 24-hour ambulatory blood pressure measurements are performed after nurse-administered medication.
Exclusion Criteria:
Patients who are not eligible for randomization but treated with renal artery stenting outside the protocol are followed according to the DAN-PTRAII protocol in order to account for all PTRA treatments performed in Denmark in the study period.
Patients treated with renal artery stenting without randomization in the study period include patients with:
At least one of the listed high-risk clinical syndromes AND one or more significant atherosclerotic renal artery stenoses defined as a stenosis of 50-69% by catheter-based angiography with:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Percutaneous transluminal renal angioplasty with stent placement
Drug: Optimal medical therapy (OMT) · Diagnostic Test: Catheter-based angiography · Diagnostic Test: Measurement of translesional pressure gradients · Procedure: Renal artery stenting
Sham procedure
Drug: Optimal medical therapy (OMT) · Diagnostic Test: Catheter-based angiography · Diagnostic Test: Measurement of translesional pressure gradients · Procedure: Sham (No Treatment)
Optimal medical therapy, including maximally tolerated renin-angiotensin system blockade with either an angiotensin-converting enzyme inhibitor or an angiotensin II receptor blocker.
Catheter-based angiography performed in accordance with the study protocol.
Measurement of translesional pressure gradients performed in accordance with the study protocol.
Renal artery stenting performed in accordance with the study protocol.
Sham procedure performed in accordance with the study protocol.
Change in 24-hour ambulatory systolic blood pressure
Defined as the between-group difference in the change in 24-hour ambulatory systolic blood pressure from baseline to 6 months.
Time frame: Baseline and 6 months
Change in estimated glomerular filtration rate (eGFR)
Defined as the between-group difference in the change in estimated glomerular filtration rate (eGFR) from baseline to 6 months.
Time frame: Baseline, Day 1, Day 7, Day 21, 6 weeks, 3 months, 4.5 months, and 6 months
Change in urine albumin-to-creatinine ratio (UACR)
Defined as the between-group difference in the change in urine albumin-to-creatinine ratio from baseline to 3 and 6 months.
Time frame: Baseline, 3 months, and 6 months
Change in attended automated office systolic blood pressure
Defined as the between-group difference in the change in attended automated office systolic blood pressure from baseline to 3 and 6 months.
Time frame: Baseline, 3 months, and 6 months
Change in unattended automated office systolic blood pressure
Defined as the between-group difference in the change in unattended automated office systolic blood pressure from baseline to 3 and 6 months.
Time frame: Baseline, 3 months, and 6 months
Change in defined daily dose (DDD) of antihypertensive medications
Defined as the between-group difference in the change in defined daily dose (DDD) of antihypertensive medications from baseline to 3 and 6 months.
Time frame: Baseline, 3 months, and 6 months
Change in the number of antihypertensive medications
Defined as the between-group difference in the change in the number of antihypertensive medications from baseline to 3 and 6 months.
Time frame: Baseline, 3 months, and 6 months
Change in 24-hour ambulatory systolic blood pressure (corrected for changes in antihypertensive medication)
Defined as the between-group difference in the change in 24-hour ambulatory systolic blood pressure from baseline to 3 and 6 months, corrected for changes in antihypertensive medication burden (1 DDD = 5 mmHg).
Time frame: Baseline, 3 months, and 6 months
Number of participants with cardiovascular or kidney outcomes
Between-group comparison of the number of participants with clinical events from baseline to 6 months. Clinical events are defined using the same criteria as in the Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL) trial, except for progressive renal insufficiency (defined in CORAL as a reduction from baseline of 30% or more in estimated GFR). Clinical events included in the composite endpoint from baseline to 6-month follow-up are: 1. Death from cardiovascular causes 2. Death from renal causes 3. Stroke 4. Myocardial infarction 5. Hospitalization for congestive heart failure 6. Progressive renal insufficiency (a reduction from baseline of 50% or more in estimated GFR) 7. Permanent renal-replacement therapy Only the first event per participant is included in the composite.
Time frame: From baseline to 6 months
Number of deaths from any cause
Between-group comparison of the number of participants with death from any cause from baseline to 6 months.
Time frame: From baseline to 6 months
Change in health status on 12-item Short Form Health Survey (SF-12)
Defined as the between-group difference in the change in 12-item Short Form Health Survey (SF-12) scores from baseline to 3 and 6 months. Scores range from 0 to 100, with higher scores indicating better physical and mental health functioning.
Time frame: Baseline, 3 months, and 6 months
Number of serious adverse events (SAEs) during follow-up and procedure-related and postoperative adverse events within 30 days after the procedure
All SAEs occurring from baseline to 6 months, as well as procedure-related adverse events (≤24 hours) and postoperative adverse events (\>24 hours) occurring within 30 days after the procedure, will be systematically recorded and compared between groups as the proportion of participants with at least one event. Events include, but are not limited to: 1. Death from any cause 2. Rupture, dissection, occlusion, or perforation of the renal artery 3. Stent thrombosis of the PTRA-treated renal artery 4. Embolic complications affecting the kidney or peripheral circulation (upper or lower extremity depending on access site) 5. Bleeding requiring transfusion 6. Embolization or nephrectomy due to bleeding or other complications 7. Access-related complications requiring treatment: bleeding, thrombosis, or pseudoaneurysm 8. Need for acute dialysis 9. Clinical events as defined above
Time frame: From baseline to 6 months (SAEs); from baseline to 30 days (procedure-related and postoperative adverse events)
Change in intrarenal resistive index
Defined as the between-group difference in the change in intrarenal resistive index (unitless) of the affected kidney from baseline to 6 months, measured by Doppler ultrasound. Additional renal ultrasound and Doppler parameters (kidney length, peak systolic velocity, acceleration time, renal-renal ratio, and pulsatility index) will be assessed at baseline and 6 months and compared between groups. In exploratory analyses, the association between baseline intrarenal resistive index (≥0.80 vs \<0.80) and the change in 24-hour ambulatory systolic blood pressure and eGFR from baseline to 6 months will be evaluated, and the diagnostic accuracy (sensitivity and specificity) of baseline Doppler ultrasound for identifying hemodynamically significant renal artery stenosis will be assessed using invasive pressure measurement as the reference standard.
Time frame: Baseline and 6 months
Change in left ventricular mass index
Defined as the between-group difference in the change in left ventricular mass index (g/m²) from baseline to 6 months, assessed by transthoracic echocardiography. Additional transthoracic echocardiographic parameters of cardiac systolic and diastolic function and cardiac chamber dimensions and volumes will be assessed at baseline and 6 months and compared between groups.
Time frame: Baseline and 6 months
Change in split renal function of the affected kidney
Defined as the between-group difference in the change in split renal function (%) of the affected kidney from baseline to 6 months, assessed by renography. The change in renogram configuration (renogram grade) of the affected kidney from baseline to 6 months will be compared between groups as the proportion of participants with improvement in renogram grade. In exploratory analyses, the diagnostic accuracy (sensitivity and specificity) of baseline renography for identifying hemodynamically significant renal artery stenosis will be assessed using invasive pressure measurement as the reference standard, and the association between baseline renography with intermediate/high probability of renal artery stenosis and the change in 24-hour ambulatory systolic blood pressure and eGFR from baseline to 6 months will be evaluated.
Time frame: Baseline and 6 months
Translesional pressure ratio (Pd/Pa) across renal artery stenoses
Defined as the distal-to-aortic pressure ratio (Pd/Pa, unitless) across the target renal artery stenosis, measured by intra-arterial pressure assessment during the endovascular procedure. Systolic, diastolic, mean, and pulse pressure gradients (mmHg) across the target renal artery stenosis will be measured invasively during the procedure. In exploratory analyses, the association between baseline Pd/Pa and mean and systolic translesional pressure gradients and the change in 24-hour ambulatory systolic blood pressure and eGFR from baseline to 6 months will be evaluated, and whether the effect of PTRA differs according to baseline Pd/Pa will be explored.
Time frame: Baseline and 6 months
Agreement between CFD-derived and invasively measured translesional pressure ratio (Pd/Pa)
Defined as the mean difference (Bland-Altman bias, unitless) between Pd/Pa derived non-invasively from CT angiography using computational fluid dynamics (CFD) and Pd/Pa measured invasively during the endovascular procedure. Agreement between CFD-derived and invasively measured mean and systolic translesional pressure gradients will be assessed correspondingly. In exploratory analyses, the association between CFD-derived Pd/Pa and mean and systolic translesional pressure gradients and the change in 24-hour ambulatory systolic blood pressure and eGFR from baseline to 6 months will be evaluated.
Time frame: Baseline and 6 months
Change in plasma renin
Defined as the between-group difference in the change in plasma renin concentration (mIU/L) from baseline to 3 and 6 months. In exploratory analyses, the association between baseline plasma renin and the change in 24-hour ambulatory systolic blood pressure and eGFR from baseline to 6 months will be evaluated.
Time frame: Baseline, 3 months, and 6 months
Change in plasma aldosterone
Defined as the between-group difference in the change in plasma aldosterone concentration (pmol/L) from baseline to 3 and 6 months. In exploratory analyses, the association between baseline plasma aldosterone and the change in 24-hour ambulatory systolic blood pressure and eGFR from baseline to 6 months will be evaluated.
Time frame: Baseline, 3 months, and 6 months
Change in N-terminal pro-B-type natriuretic peptide (NT-proBNP)
Defined as the between-group difference in the change in plasma NT-proBNP concentration (ng/L) from baseline to 3 and 6 months. In exploratory analyses, the association between changes in echocardiographic parameters, including left ventricular mass index, and the change in NT-proBNP from baseline to 6 months will be evaluated to assess whether changes in NT-proBNP reflect changes in cardiac structure and function.
Time frame: Baseline, 3 months, and 6 months
Proteomic profile in blood and on the angioplasty balloon
Defined as the proteomic profile in blood and in material retrieved from the angioplasty balloon after dilation during PTRA. In exploratory analyses, the association between the proteomic profile and the change in 24-hour ambulatory systolic blood pressure and eGFR from baseline to 6 months, and the need for reintervention due to restenosis, will be evaluated. Proteomic analyses will be described in a separate analysis plan.
Time frame: Baseline and 6 months
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Started Jun 2023 (actual). Primary completion is estimated for Jun 2027, 47 months after the start.
Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 47 months is above that.
Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.